Company Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 08/07/2025			5-day change	1st Jan Change
175,500.00 ^KRW	-1.85%		+9.96%	-2.66%

07-04	Celltrion Holdings to Buy KRW500 Billion in Celltrion Shares, Eyes Portfolio Expansion	MT
06-26	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 20, 2025.	CI

Business description: Celltrion, Inc.

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Number of employees: 2,391

Sales by Activity: Celltrion, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Biopharmaceutical	1,690B	1,616B	1,937B	1,873B	6,070B
Chemical Drugs	242B	557B	654B	501B	531B
Other	2.63B	3.05B	3.88B	5.14B	5.82B
Intersectoral Insider Transaction Reconciliation	-85.76B	-264B	-311B	-203B	-3,050B

See all business segments

Geographical breakdown of sales: Celltrion, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
South Korea	1,542B	2,015B	2,324B	2,262B	4,184B
Europe	-	-	-	-	1,862B
Asia	-	76.42B	140B	117B	252B
North America	-	-	-	-	168B
Central and South America	-	-	-	-	141B
Americas	-	84.61B	131B	-	-
Foreign	308B	-	-	-	-
Consolidation Adjustment	-	-264B	-311B	-203B	-3,050B

See all geographic segments

Executive Committee: Celltrion, Inc.

Manager	Title	Age	Since
Wu-Sung Ki CEO	Chief Executive Officer	-	19/03/2015
Ho-Seop Lee DFI	Director of Finance/CFO	50	-
Sung-Han Lee CMP	Compliance Officer	43	-
Yoon-Mo Koo PRN	Corporate Officer/Principal	55	-
Sang-Joon Lee PRN	Corporate Officer/Principal	58	-

See CELLTRION, INC. governance

Composition of the Board of Directors: Celltrion, Inc.

Director	Title	Age	Since
Jung-Jin Seo CHM	Chairman	67	-
Dong-Il Kim BRD	Director/Board Member	66	16/07/2008
Joseph Lee BRD	Director/Board Member	67	16/07/2008
Gyun-Seok Cho BRD	Director/Board Member	65	19/03/2009
Byung-Hoon Jeon BRD	Director/Board Member	67	26/03/2014
Jong-Seok Lee BRD	Director/Board Member	73	07/12/2014
Geun-Young Kim BRD	Director/Board Member	65	-
Dae-Hyeon Yoo BRD	Director/Board Member	66	-
Soon-Woo Lee BRD	Director/Board Member	74	-
Jae-Sik Lee BRD	Director/Board Member	67	-

Composition of the Board of Directors

Shareholders: Celltrion, Inc.

Name	Equities	%	Valuation
Jung-Jin Seo 28.84 %	66,724,715	28.84 %	7 891 M ₩
National Pension Service of Korea 6.389 %	14,779,671	6.389 %	1 748 M ₩
CELLTRION, INC. 2.36 %	5,460,210	2.36 %	646 M ₩
State Street Global Advisors Ltd. 0.2052 %	474,580	0.2052 %	56 M ₩
Sjunde AP-fonden 0.1545 %	357,281	0.1545 %	42 M ₩

List of CELLTRION, INC. shareholders

Holdings: Celltrion, Inc.

Name	Equities	%	Valuation
CELLTRION PHARM, INC. 54.8%	23,937,492	54.8%	880,628,733 $
CELLTRION, INC. 2.36%	5,460,210	2.36%	645,709,474 $

Company details: Celltrion, Inc.

Celltrion, Inc.

23 Academy-ro Yeonsu-gu

22014, Inchon

+82 3 2850 5000

http://www.celltrion.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CELLTRION, INC.	-1.85%	+9.96%	+3.15%	+6.30%	28.26B
LONZA GROUP AG	-0.43%	-1.66%	+10.63%	+0.40%	49.23B
BEONE MEDICINES LTD.	+1.44%	-0.28%	+69.36%	+29.53%	28.96B
IQVIA HOLDINGS INC.	+1.24%	+1.14%	-21.28%	-25.02%	28.45B
EUROFINS SCIENTIFIC SE	-1.00%	-1.26%	+24.51%	-22.51%	12.53B
ICON PUBLIC LIMITED COMPANY	+2.70%	+1.81%	-52.77%	-30.45%	12.05B
QIAGEN N.V.	+0.67%	-0.75%	+15.61%	-6.57%	10.36B
ASCENDIS PHARMA A/S	-4.44%	-2.23%	+23.24%	+79.65%	10.18B
TEMPUS AI, INC.	+0.86%	-1.57%	+76.23%	-	10.13B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+4.77%	+32.26%	+22,327.41%	+1,831.00%	9.55B
Average	-0.23%	+3.10%	+2,247.61%	+206.92%	19.97B
Weighted average by Cap.	-0.10%	+1.61%	+1,081.93%	+94.53%